The Impact of Sarcopenia on Post-COVID Pulmonary Sequelae

Year 2025, Volume: 4 Issue: 1, 1 - 9, 27.03.2025

Yusuf Dedecan , Murathan Köksal , Mehmet Kutlu

Abstract

Introductıon: Following COVID-19 pneumonia, some patients experience symptoms such as weakness, fatigue, dyspnea, exertional dyspnea, and a persistent cough. This condition is defined as post-COVID-19 syndrome. Residual chest CT findings can be detected in some of these patients. Sarcopenia, a concept reflecting skeletal muscle mass loss, is a condition that occurs during the development of many diseases. This study aims to investigate the impact of sarcopenia on pulmonary sequelae following COVID-19 infection.
Methods: A total of 142 patients were included in our study. Among them, 73 patients had post-COVID sequelae on CT scans and served as the patient group, while 69 patients had no sequelae on CT scans and formed the control group. Muscle measurements derived from thoracic CT scans were manually obtained using PACS software. The areas and densities of the total pectoral muscles at the upper half level of the T4 vertebra and the paraspinal muscles at the lower half level of the T12 vertebra were recorded.
Results: There were no statistically significant differences in the mean values of T4 vertebra total pectoral muscle area, T12 vertebra paraspinal muscle area, T4 vertebra pectoral muscle density and T12 vertebra paraspinal muscle density between the groups. However, both the patient and control groups were sarcopenic according to reference values
Conclusion: In our study, we could not find an association between lung CT findings, respiratory symptoms of the patients, and sarcopenia, which was the main focus. We attributed this to the separate mechanisms and pathophysiological processes of sarcopenia and pulmonary sequelae.

Keywords

Sarcopenia, Post-COVID sequelae, Pectoral muscle area, Paraspinal muscle area, Thorax CT

References

• 1. WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected Interim guidance. https://apps.who.int/iris/bitstream/handle/10665/330893/WHO-nCoV-Clinical-2020.3-eng.pdf?sequence=1&isAllowed=y (Access date: 10.10.2023).
• 2. Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia (Nathan). 2021;13(1):14. Published 2021 Dec 6. doi:10.1186/s41479-021-00092-9.
• 3. Mahase E. (2020). Covid-19: What do we know about “long covid”? BMJ, 370, m2815. doi: 10.1136/bmj.m2815.
• 4. Funk G.C., Nell C., Pokieser W., et al. (2021). Organizing pneumonia following Covid19 pneumonia. Wien Klin Wochenschr, 133(17-18), 979-982. doi: 10.1007/s00508-021-01852-9.
• 5. Konopka KE, Perry W, Huang T, Farver CF, Myers JL. Usual Interstitial Pneumonia is the Most Common Finding in Surgical Lung Biopsies from Patients with Persistent Interstitial Lung Disease Following Infection with SARS-CoV-2. EClinicalMedicine. 2021;42:101209. doi:10.1016/j.eclinm.2021.101209.
• 6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis [published correction appears in Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046]. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.
• 7. Rosenberg I.H. (1997). Sarcopenia: origins and clinical relevance. The Journal of nutrition, 127(5), 990S-991S. doi: 10.1093/jn/127.5.990S.
• 8. Correa-de-Araujo R., Addison O., Miljkovic I., et al. (2020). Myosteatosis in the context of skeletal muscle function deficit: An interdisciplinary workshop at the National Institute on Aging. Frontiers in Physiology, 11, 963. doi: 10.3389/fphys.2020.00963.
• 9. Ufuk F., Demirci M., Sagtas E., et al. (2020). The prognostic value of pneumonia severity score and pectoralis muscle area on chest CT in adult COVID-19 patients. European Journal of Radiology, 131, 109271. doi: 10.1016/j.ejrad.2020.109271.
• 10. Derstine B.A., Holcombe S.A., Goulson R.L., et al. (2016). Quantifying sarcopenia reference values using lumbar and thoracic muscle areas in a healthy population. The Journal of Nutrition, Health & Aging, 21(9), 975-981. doi: 10.1007/s12603-017-0983-3.
• 11. Chianca V., Albano D., Messina C., et al. (2021). Sarcopenia: Imaging assessment and clinical application. Abdominal Radiology, 46(7), 2981-2992. doi:10.1007/s00261-021-03294-3.
• 12. Antonarelli M., Fogante M. (2022). Chest CT-Derived Muscle Analysis in COVID-19 Patients. Tomography, 8(1), 414-422. doi: 10.3390/tomography8010034.
• 13. Strassmann D, Hensen B, Grünwald V, et al. Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. International Journal of Clinical Oncology. 2021;26(11):2151-2160. doi:10.1007/s10147-021-01997-7.
• 14. Çınar HU, Çelik B, Taşkın G, İnce Ö. Low thoracic muscle mass index on computed tomography predicts adverse outcomes following lobectomy via thoracotomy for lung cancer. Interact Cardiovasc Thorac Surg. 2021;33(5):712-720. doi:10.1093/icvts/ivab150.
• 15. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30(12):6808-6817. doi:10.1007/s00330-020-07033-y.
• 16. Cherrez-Ojeda I, Cortés-Telles A, Gochicoa-Rangel L, et al. Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population. J Pers Med. 2022;12(9):1393. Published 2022 Aug 27. doi:10.3390/jpm12091393.
• 17. Bocchino M., Lieto R., Romano F., et al. (2022). Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia. Radiology, 305(2), 479-485. doi: 10.1148/radiol.220019.
• 18. Molwitz I, Ozga A K, Gerdes L, et al. Prediction of abdominal CT body composition parameters by thoracic measurements as a new approach to detect sarcopenia in a COVID-19 cohort. Scientific reports,2022,12(1),6443. doi:10.1038/s41598-022-10266-0
• 19. Kim JW, Yoon JS, Kim EJ, et al. Prognostic Implication of Baseline Sarcopenia for Length of Hospital Stay and Survival in Patients With Coronavirus Disease 2019. J Gerontol A Biol Sci Med Sci. 2021;76(8):e110-e116. doi:10.1093/gerona/glab085.
• 20. Schiaffino S, Albano D, Cozzi A, et al. CT-derived Chest Muscle Metrics for Outcome Prediction in Patients with COVID-19. Radiology. 2021;300(2):E328-E336. doi:10.1148/radiol.2021204141.
• 21. Kinsey C.M., San José Estépar R., Van Der Velden J., et al. (2017). Lower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(1):38-43. doi:10.1158/1055-9965.EPI-15-1067.
• 22. Moon SW, Choi JS, Lee SH, et al. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res. 2019;20(1):35. Published 2019 Feb 15. doi:10.1186/s12931-019-1001-6
• 23. Ince, Nursima, Ozlem Altindag, Can Demirel, and Kamil Ince. “The Frequency of Sarcopenia in the Post-COVID Period and Its Relationship With the Clinical Course of the COVID-19”. Annals of Medical Research 29, no. 12 (December 23, 2022): 1389–1392. https://www.annalsmedres.org/index.php/aomr/article/view/4320. (Access date: 10.10.2023).
• 24. Soares M N, Eggelbusch M, Naddaf E, et al. Skeletal muscle alterations in patients with acute Covid‐19 and post‐acute sequelae of Covid‐19. Journal of cachexia, sarcopenia and muscle,2022,13(1),11-22. doi:10.1002/jcsm.12896.
• 25. Evcik D. (2023). Musculoskeletal involvement: COVID-19 and post-COVID-19. Turkish Journal of Physical Medicine and Rehabilitation, 69(1), 1-7. doi: 10.5606/tftrd.2023.12521.
• 26. Zheng KI, Feng G, Liu WY, Targher G, Byrne CD, Zheng MH. Extrapulmonary complications of COVID-19: A multisystem disease?. J Med Virol. 2021;93(1):323-335. doi:10.1002/jmv.26294.